CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $21M, lower than 95% of all stocks globally
- FinancialsAltman Z-Score -3.24: distress zone
- Interpretations2 currently firing — 2
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
15.55MGBP21.00M · vs all stocks (USD)
Revenue (TTM)
1.38MGBP1.86M · vs all stocks (USD)
Profit Margin
-178.52%vs Biotechnology peers
Beta
0.9020xvs all stocks
52-Week Change
35.14%vs all stocks
Market Capitalization
15.55MGBP21.00M · vs all stocks (USD)
Enterprise Value
11.31MGBP15.27M · vs all stocks (USD)
Price to Sales (TTM)
11.28xvs Biotechnology peers
Price to Book (MRQ)
4.50xvs Biotechnology peers
Enterprise to Revenue
8.21xvs Biotechnology peers
Enterprise to EBITDA
-4.63xvs Biotechnology peers
Profit Margin
-178.52%vs Biotechnology peers
Operating Margin
-149.52%vs Biotechnology peers
Return on Assets (TTM)
-40.16%vs Biotechnology peers
Return on Equity (TTM)
-102.18%vs Biotechnology peers
Revenue (TTM)
1.38MGBP1.86M · vs all stocks (USD)
Revenue per Share (TTM)
0.0010GBPUpdated Jul 22, 2026Quarterly Revenue Growth
26.80%vs Biotechnology peers
Gross Profit (TTM)
672.00KGBP907.56K · vs all stocks (USD)
EBITDA (TTM)
-2.44MGBP-3.30M · vs all stocks (USD)
Net Income (TTM)
-2.46MGBP-3.32M · vs all stocks (USD)
Operating Cash Flow (TTM)
-1.86MGBP-2.52M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-1.25MGBP-1.68M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.00GBPUpdated Jul 22, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
1.20MGBPFY2025 · Jun 30, 2025Cost of Goods Sold
624.00KGBPFY2025 · Jun 30, 2025Gross Profit
579.00KGBPFY2025 · Jun 30, 2025Operating Income
-2.65MGBP-3.57M · vs all stocks (USD)
Pre-tax Income
-2.57MGBPFY2025 · Jun 30, 2025Income Tax Expense
-145.00KGBPFY2025 · Jun 30, 2025Net Income
-2.42MGBPFY2025 · Jun 30, 2025EBIT
-2.51MGBPFY2025 · Jun 30, 2025EBITDA (Income Statement)
-2.28MGBPFY2025 · Jun 30, 2025Selling, General & Administrative
2.93MGBPFY2025 · Jun 30, 2025Non-operating Interest Income
27.00KGBPFY2025 · Jun 30, 2025Non-operating Interest Expense
56.00KGBPFY2025 · Jun 30, 2025EPS (Basic)
-0.0014GBPFY2025 · Jun 30, 2025EPS (Diluted)
-0.0014GBPFY2025 · Jun 30, 2025Basic Shares Outstanding
1.79BSharesFY2025 · Jun 30, 2025Diluted Shares Outstanding
1.79BSharesFY2025 · Jun 30, 2025Net Income from Continuing Operations
-2.42MGBPFY2025 · Jun 30, 2025Preferred Stock Dividends
0.00GBPFY2025 · Jun 30, 2025Operating Cash Flow
-2.11MGBPFY2025 · Jun 30, 2025Free Cash Flow
-2.12MGBPFY2025 · Jun 30, 2025Cash & Cash Equivalents (End of Period)
1.06MGBPFY2025 · Jun 30, 2025Starting Profit (CF Statement)
-2.42MGBPFY2025 · Jun 30, 2025Stock-based Compensation
116.00KGBPFY2025 · Jun 30, 2025Other Non-cash Items
252.00KGBPFY2025 · Jun 30, 2025Change in Accounts Receivable (CF)
-97.00KGBPFY2025 · Jun 30, 2025Change in Other Assets/Liabilities
39.00KGBPFY2025 · Jun 30, 2025Capital Expenditures
-10.00KGBPFY2025 · Jun 30, 2025Net Intangibles (CF)
-82.00KGBPFY2025 · Jun 30, 2025Net Investing Cash Flow
-10.00KGBPFY2025 · Jun 30, 2025Long-term Debt Payments
-38.00KGBPFY2025 · Jun 30, 2025Net Financing Cash Flow
2.85MGBPFY2025 · Jun 30, 2025Shares Outstanding
2.93BSharesUpdated Jul 22, 2026Float Shares
2.18BSharesUpdated Jul 22, 2026% Held by Insiders
24.43%vs all stocks
% Held by Institutions
9.41%vs all stocks
Total Cash (MRQ)
1.53MGBP2.06M · vs all stocks (USD)
Total Cash per Share (MRQ)
0.0010GBPUpdated Jul 22, 2026Total Debt (MRQ)
333.00KGBP449.73K · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.1478xvs Biotechnology peers
Current Ratio (MRQ)
2.04xvs Biotechnology peers
Book Value per Share (MRQ)
0.0010GBPUpdated Jul 22, 2026Total Assets
2.83MGBP3.83M · vs all stocks (USD)
Total Current Assets
1.82MGBPFY2025 · Jun 30, 2025Total Liabilities
1.45MGBPFY2025 · Jun 30, 2025Total Non-current Assets
1.01MGBPFY2025 · Jun 30, 2025Total Non-current Liabilities
277.00KGBPFY2025 · Jun 30, 2025Total Current Liabilities
1.18MGBPFY2025 · Jun 30, 2025Cash
1.06MGBPFY2025 · Jun 30, 2025Cash & Cash Equivalents
1.06MGBPFY2025 · Jun 30, 2025Accounts Receivable
229.00KGBPFY2025 · Jun 30, 2025Inventory
80.00KGBPFY2025 · Jun 30, 2025Accounts Payable
414.00KGBPFY2025 · Jun 30, 2025Short-term Debt
249.00KGBPFY2025 · Jun 30, 2025Long-term Debt
242.00KGBPFY2025 · Jun 30, 2025Common Stock (Book)
1.99MGBPFY2025 · Jun 30, 2025Retained Earnings
-15.05MGBPFY2025 · Jun 30, 2025Total Shareholders' Equity
1.38MGBP1.87M · vs all stocks (USD)
52-Week Low
0.3200GBXUpdated Jul 22, 202652-Week High
1.57GBXUpdated Jul 22, 202652-Week Change
35.14%vs all stocks
Beta
0.9020xvs all stocks
50-Day MA
0.5260GBXUpdated Jul 22, 2026200-Day MA
0.7497GBXUpdated Jul 22, 2026Avg 10-Day Volume
1.91MSharesUpdated Jul 22, 2026Avg 30-Day Volume
3.50MSharesUpdated Jul 22, 2026Diluted EPS (TTM)
-0.0014GBPUpdated Jul 22, 20262 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Multi-Year Debt Decrease With Cash Near Total Debt And Equity
Long-term debt down in each of four years, and cash now covers most or all of what is left.
Reads
Where is this company structurally exposed?
Ulcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
It sits well below its peak, and the fall has been both deep and long.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
Looks liquid, but the distress score says otherwiseNotable
Current Ratio: 2.04Altman Z-Score: -3.24
Financial Health
Altman Z-Score -3.24: distress zoneCritical
Altman Z-Score: -3.24
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $21M, lower than 95% of all stocks globallySignificant
Market cap (USD): 20,998,239.535Global P5: 269,387,740.27
Revenue is $1.86M, lower than 95% of all stocks globallySignificant
Revenue (USD): 1,861,030.34Global P5: 30,274,777.221
Companies that share the same coordination system — how they create, deliver, or capture value.
Rua Life Sciences Plc
Tier 1ProductionApproval-Gated PipelineRule
Inspiration Healthcare Group plc
Tier 1ProductionApproval-Gated PipelineRule
ImmuPharma PLC
Tier 1ProductionApproval-Gated PipelineRuleRisk
BioLineRx Ltd.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Genflow Biosciences Plc
Tier 1ProductionApproval-Gated PipelineRuleRisk
Cizzle Biotechnology Holdings Plc
Tier 1ProductionApproval-Gated PipelineRule
SkinBioTherapeutics Plc
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Crism Therapeutics Corporation
Tier 1ProductionApproval-Gated PipelineRuleRisk
Sailong Pharmaceutical Group Inc.
Tier 1ProductionApproval-Gated PipelineRule
Context Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Creative & Innovative System Inc.
2 interpretationsMulti-Year Debt Decrease With Cash Near Total Debt And EquityUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
Doximity Inc.
2 interpretationsMulti-Year Debt Decrease With Cash Near Total Debt And EquityUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
Hesai Group
2 interpretationsMulti-Year Debt Decrease With Cash Near Total Debt And EquityUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated